Skip to main content
main-content

15-06-2021 | ASCO 2021 | Conference coverage | Video

IMpower010 supports adjuvant atezolizumab in early-stage NSCLC

Heather Wakelee talks through the efficacy and safety data from the IMpower010 study of postoperative atezolizumab in individuals with early-stage non-small-cell lung cancer, touching on the cost aspect and outlining the key unanswered questions (9:24).

00:00 - Efficacy data from IMpower010
03:45 - Side effects and costs
06:34 - Summary of the conclusions
07:15 - Key unanswered questions

Read transcript

Image Credits